Published in Eur J Immunol on June 01, 1974
T-lymphocyte-enriched murine peritoneal exudate cells. II. Genetic control of antigen-induced T-lymphocyte proliferation. J Exp Med (1976) 2.27
Cellular and genetic control of antibody responses in vitro. III. Immune response gene regulation of accessory cell function. J Exp Med (1978) 1.99
Antigen-specific T-cell factors in the genetic control of the immune response to poly(Tyr,Glu)-polyDLAla--polyLys. Evidence for T- and B-cell defects in SJL mice. J Exp Med (1975) 1.98
Genetic regulation of delayed-type hypersensitivity responses to poly(LTyr,LGu)-poly(DLAla)--poly(LLys). I. Expression of the genetic defect at two phases of the immune process. J Exp Med (1980) 1.11
Role of antigenic structure in cell to cell cooperation. Proc Natl Acad Sci U S A (1976) 1.04
Genetic control of immune response. The dose of antigen given in aqueous solution is critical in determining which mouse strain is high responder to poly(LTyr, LGlu)-poly(LPro)--poly(LLys). J Exp Med (1975) 0.96
Genetic regulation of delayed-type hypersensitivity responses to poly (Tyr,Glu)-poly(DLAla)--poly(Lys): expression of the genetic defect in the induction and manifestation phases in H-2s and H-2f mice. Immunology (1982) 0.75
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
A TH1-->TH2 switch is a critical step in the etiology of HIV infection. Immunol Today (1993) 10.43
Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. J Exp Med (1965) 7.27
Cell-mediated cytotoxicity to trinitrophenyl-modified syngeneic lymphocytes. Eur J Immunol (1974) 6.20
Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol (1991) 4.69
Modulation of inflammation and immunity by cyclic AMP. Science (1974) 4.31
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J (1996) 4.26
Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest (1989) 3.92
Human cytotoxic response in vitro to trinitrophenyl-modified autologous cells. I. T cell recognition of TNP in association with widely shared antigens. J Immunol (1978) 3.90
Role of the murine major histocompatibility complex in the specificity of in vitro T-cell-mediated lympholysis against chemically-modified autologous lymphocytes. Transplant Rev (1976) 3.87
Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis (1992) 3.27
Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest (1993) 3.19
Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J Clin Invest (1994) 3.12
The localization of antigen in relation to specific antibody-producing cells. I. Use of a synthetic polypeptide [(T,G)-A--L] labelled with iodine-125. Immunology (1966) 3.09
Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur J Immunol (1977) 3.05
The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today (1994) 3.01
Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev (1996) 2.77
Cellular differentiation of the immune system of mice. I. Separate splenic antigen-sensitive units for different types of anti-sheep antibody-forming cells. J Exp Med (1968) 2.51
Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst (1997) 2.45
Genetic control of the antibody response. II. Further analysis of the specificity of determinant-specific control, and genetic analysis of the response to (H,G)-A--L in CBA and C57 mice. J Exp Med (1967) 2.41
Antigenicity of some new synthetic polypeptides and polypeptidyl gelatins. Biochem J (1964) 2.40
Purification of antibodies with immunoadsorbents prepared using bromoacetyl cellulose. Immunochemistry (1967) 2.35
Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science (1993) 2.35
Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res (2000) 2.33
A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS). J Immunol (1986) 2.31
Dependence of the chemical nature of antibodies on the net electrical charge of antigens. Proc Natl Acad Sci U S A (1966) 2.25
The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci U S A (1999) 2.22
Role of optical configuration in the immunogenicity and specificity of synthetic antigens derived from multichain polyproline. J Biol Chem (1968) 2.19
An immunoendocrinological hypothesis of HIV infection. Lancet (1994) 2.19
Antigen-specific thymus cell factors in the genetic control of the immune response to poly-(tyrosyl, glutamyl)-poly-D, L-alanyl--poly-lysyl. J Exp Med (1974) 2.19
Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol (1991) 2.17
Bifunctional major histocompatibility-linked genetic regulation of cell-mediated lympholysis to trinitrophenyl-modified autologous lymphocytes. J Exp Med (1975) 2.14
Immunological studies with synthetic polypeptides. Adv Immunol (1966) 2.10
Antiviral response elicited by a completely synthetic antigen with built-in adjuvanticity. Proc Natl Acad Sci U S A (1980) 2.07
Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res (2000) 2.07
Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol (2000) 2.05
Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J (1998) 2.04
ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J Clin Invest (1995) 2.04
Modified stock-eye ocular prosthesis. J Prosthet Dent (1985) 2.03
Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (1997) 2.00
Antigenicity: some molecular aspects. Science (1969) 1.98
Antigen-specific T-cell factors in the genetic control of the immune response to poly(Tyr,Glu)-polyDLAla--polyLys. Evidence for T- and B-cell defects in SJL mice. J Exp Med (1975) 1.98
Hemolytic plaque formation by leukocytes in vitro. Control by vasoactive hormones. J Clin Invest (1974) 1.98
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol (1971) 1.94
Early T-helper cell defects in HIV infection. AIDS (1991) 1.93
Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci U S A (1988) 1.91
Major histocompatibility complex restricted cell-mediated immunity. Adv Immunol (1977) 1.86
Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J Virol (1991) 1.83
CD8+ T cells from mice vaccinated against Toxoplasma gondii are cytotoxic for parasite-infected or antigen-pulsed host cells. J Immunol (1991) 1.82
Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature (1989) 1.80
Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med (1983) 1.79
Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A (1991) 1.78
Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J Clin Invest (1989) 1.77
The nature of the antigenic determinant in a genetic control of the antibody response. J Exp Med (1969) 1.74
B-cell alloantigens determined by the H-2 linked Ir region are associated with mixed lymphocyte culture stimulation. Science (1974) 1.73
Distinct events in the immune response elicited by transferred marrow and thymus cells. I. Antigen requirements and priferation of thymic antigen-reactive cells. J Exp Med (1969) 1.72
Regulation of antibody response by cells expressing histamine receptors. J Exp Med (1972) 1.70
In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis (1995) 1.69
H-2-restricted cytotoxic effectors generated in vitro by the addition of trinitrophenyl-conjugated soluble proteins. J Exp Med (1978) 1.68
Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. Proc Natl Acad Sci U S A (1971) 1.67
Antigen design and immune response. Harvey Lect (1973) 1.67
T-cell interactions in autoimmunity: insights from a murine model of graft-versus-host disease. Immunol Today (1989) 1.66
A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene (1997) 1.64
Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease. J Immunol (1987) 1.64
T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies. Proc Natl Acad Sci U S A (2000) 1.61
Evidence for a new segregant series of B cell antigens that are encoded in the HLA-D region and that stimulate secondary allogenic proliferative and cytotoxic responses. J Exp Med (1980) 1.61
Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope. J Infect Dis (1996) 1.61
Alloimmunization as an AIDS vaccine? Science (1993) 1.58
Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J (1997) 1.58
The genetic control of antibody specificity. J Exp Med (1969) 1.58
In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest (1988) 1.57
The beneficial effect of the estrogen antagonist, tamoxifen, on experimental systemic lupus erythematosus. J Rheumatol (1994) 1.56
Comparative genetics of nucleotide binding site-leucine rich repeat resistance gene homologues in the genomes of two dicotyledons: tomato and arabidopsis. Genetics (2000) 1.56
T cell subpopulations required for the human cytotoxic T lymphocyte response to influenza virus: evidence for T cell help. J Immunol (1981) 1.54
Functional and phenotypic alterations in T cell subsets during the course of MAIDS, a murine retrovirus-induced immunodeficiency syndrome. J Immunol (1989) 1.53
Exposure to human immunodeficiency virus (HIV) type I indicated by HIV-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies [corrected]. J Infect Dis (1991) 1.53
Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature (1988) 1.53
Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci U S A (1994) 1.53
Thymus-independence of slowly metabolized immunogens. Proc Natl Acad Sci U S A (1972) 1.52
Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A (2000) 1.52
Autoimmune manifestations in the transforming growth factor-beta 1 knockout mouse. Blood (1996) 1.51
Alloantigen-stimulated anti-HIV activity. Blood (1998) 1.51
Cellular differentiation of the immune system of mice. V. Class differentiation in marrow precursors of plaque-forming cells. J Exp Med (1969) 1.50
Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst (1988) 1.49
Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier. Proc Natl Acad Sci U S A (1979) 1.48
Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene (1996) 1.48
Changing indications for enucleations in Hadassah University Hospital, 1960-1989. Ophthalmic Epidemiol (1995) 1.48
The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res (1975) 1.48
Synthetic antigens composed exclusively of L- or D-amino acids. I. Effect of optical configuration on the immunogenicity of synthetic polypeptides in mice. Immunology (1967) 1.47